Product Registration Process (Local Manufacturing / Finished Product Import of Biologicals) for human use

Process Description for Grant of Drug Registration (Biological

Process Description:

drug - Human)

Name of Process	Drug Product Registration (Local Manufacturing / Finished Product Import - Biologicals) for human use
Name of Business process	Application for registration of drug product for local manufacturing or finished product import (biologicals) for human use
Related Laws. Rules and	 Drug Regulatory Authority of Pakistan Act, 2012. Drugs Act, 1976
regulations	 The Drugs (Labeling & Packing) Rules, 1986 The Drugs (Licensing, Registering & Advertising) Rules, 1976. The Drugs (Specification) Rules, 1978.
Input & Criteria to enter/begin	 For local manufacturer; A valid Drug Manufacturing License (Form 2) by DRAP
the business process	 For Finished product Import; A valid Drug Sale License and Sole Agency Agreement
Activities and associated documentary	Outline for registration process of biological product for human use is as follows: -
requirements	1. Registration Board is the relevant forum for consideration of
	registration applications
	2. Applicant shall submit product registration application form as per Rules 26 of Drugs (Licensing, Registering &Advertising) Rules, 1976 according to product type, as follows: -
	For Human Use:
	• Form 5F—For all types of human drug products* (*Common Technical Document (CTD) (Form 5F) is applicable with effect from 07-Mar-2019 for all human pharmaceutical and biological product including local manufacturing, imported finished drug products, new drug formulation, etc.)
	3. Applicant (manufacturer / importer) shall support product registration application with requisite documents and fee.
	4. Pre-Screening of application is performed by designated officer of DRAP and if application is incomplete, applicant is being informed.
	5. In case of complete application, applicant submits the application to DRAP.
	6. DRAP receives the application(s) which alongwith details is/are entered in the database of received applications after its categorization (routine/priority).
	7. These applications are scrutinized and evaluated on FIFO basis as per checklist approved by Registration Board.

02



drug - Human)

with observation note. One reminder is issued in case applicant fails to reply in stipulated time period. 8. After rectification of shortcomings, Biological Evaluation & Research Division of DRAP prepare the summary for consideration of Registration Board. 9. For locally manufactured drugs, Registration Board may cause the premises of drug manufacturer to be inspected by a panel of expert and detail report shall be presented before the Registration Board. 10. For imported drugs, GMP inspection of foreign manufacturer is carried out prior to grant of registration as per the policy or inspection of manufacturers abroad. 11. Registration Board takes the final decision. 12. If the Registration Board rejects the application, BE&R Division informs the applicant (manufacturer /importer) for rejection o application. 13. If MRP is already fixed by Federal Government, Biologica Evaluation & Research Division of DRAP issues Certificate o Registration of approved drug product to the applicant (manufacture / importer). 14. In case, the MRP is not fixed, matter is referred to Costing & Pricing Division for fixation of price by the Federal Government under the Drug Pricing Policy. The certificate of registration will be issued afte price fixation by Federal Government. 15. In case rejection of application by Registration Board, applicant has the right of appeal within 60 days before the Appellate Board. 16. Certificate of Registration (Form 6) of drug product from DRAF office. 17. Validity for 5 years (unless earlier cancelled or suspended by the Registration Board) 18. Legal Reference: Drug Regulatory Authority of Pakistan Act, 2012 and The Drug (Licensing, Registering & Advertising) Rules, 1976 18. Minimum: 18 months 19. Minimum: 18 months	urug - Humun)	
with observation note. One reminder is issued in case applicant fails to reply in stipulated time period. 8. After rectification of shortcomings, Biological Evaluation & Research Division of DRAP prepare the summary for consideration of Registration Board. 9. For locally manufactured drugs, Registration Board may cause the premises of drug manufacturer to be inspected by a panel of expert and detail report shall be presented before the Registration Board. 10. For imported drugs, GMP inspection of foreign manufacturer is carried out prior to grant of registration as per the policy or inspection of manufacturers abroad. 11. Registration Board takes the final decision. 12. If the Registration Board rejects the application, BE&R Division informs the applicant (manufacturer /importer) for rejection of application. 13. If MRP is already fixed by Federal Government, Biologica Evaluation & Research Division of DRAP issues Certificate of Registration of approved drug product to the applicant (manufacture / importer). 14. In case, the MRP is not fixed, matter is referred to Costing & Pricing Division for fixation of price by the Federal Government under the Drug Pricing Policy. The certificate of registration will be issued afte price fixation by Federal Government. 15. In case rejection of application by Registration Board, applicant has the right of appeal within 60 days before the Appellate Board. 16. Certificate of Registration (Form 6) of drug product from DRAF office. 17. Validity for 5 years (unless earlier cancelled or suspended by the Registration Board) 18. Legal Reference: Drug Regulatory Authority of Pakistan Act, 2012 and The Drug (Licensing, Registering & Advertising) Rules, 1976 18. Minimum: 03 months 18. Maximum: 18 months		
9. For locally manufactured drugs, Registration Board may cause the premises of drug manufacturer to be inspected by a panel of experts and detail report shall be presented before the Registration Board. 10. For imported drugs, GMP inspection of foreign manufacturer is carried out prior to grant of registration as per the policy or inspection of manufacturers abroad. 11. Registration Board takes the final decision. 12. If the Registration Board rejects the application, BE&R Division informs the applicant (manufacturer /importer) for rejection of application. 13. If MRP is already fixed by Federal Government, Biologica Evaluation & Research Division of DRAP issues Certificate of Registration of approved drug product to the applicant (manufacture / importer). 14. In case, the MRP is not fixed, matter is referred to Costing & Pricing Division for fixation of price by the Federal Government under the Drug Pricing Policy. The certificate of registration will be issued afte price fixation by Federal Government. 15. In case rejection of application by Registration Board, applicant has the right of appeal within 60 days before the Appellate Board. Output Criteria to exit the business process • Validity for 5 years (unless earlier cancelled or suspended by the Registration Board) • Legal Reference: Drug Regulatory Authority of Pakistan Act, 2012 and The Drug (Licensing, Registering & Advertising) Rules, 1976 Time required to exit the business process • Minimum: 03 months • Maximum: 18 months		8. After rectification of shortcomings, Biological Evaluation & Research Division of DRAP prepare the summary for consideration
10. For imported drugs, GMP inspection of foreign manufacturer is carried out prior to grant of registration as per the policy or inspection of manufacturers abroad. 11. Registration Board takes the final decision. 12. If the Registration Board rejects the application, BE&R Division informs the applicant (manufacturer /importer) for rejection of application. 13. If MRP is already fixed by Federal Government, Biological Evaluation & Research Division of DRAP issues Certificate of Registration of approved drug product to the applicant (manufacture / importer). 14. In case, the MRP is not fixed, matter is referred to Costing & Pricing Division for fixation of price by the Federal Government under the Drug Pricing Policy. The certificate of registration will be issued after price fixation by Federal Government. 15. In case rejection of application by Registration Board, applicant has the right of appeal within 60 days before the Appellate Board. Output Criteria to exit the business process Output Criteria of Registration (Form 6) of drug product from DRAF office. Validity for 5 years (unless earlier cancelled or suspended by the Registration Board) Legal Reference: Drug Regulatory Authority of Pakistan Act, 2012 and The Drug (Licensing, Registering & Advertising) Rules, 1976 Time required to exit the business process		9. For locally manufactured drugs, Registration Board may cause the premises of drug manufacturer to be inspected by a panel of experts
11. Registration Board takes the final decision. 12. If the Registration Board rejects the application, BE&R Division informs the applicant (manufacturer /importer) for rejection of application. 13. If MRP is already fixed by Federal Government, Biological Evaluation & Research Division of DRAP issues Certificate of Registration of approved drug product to the applicant (manufacture / importer). 14. In case, the MRP is not fixed, matter is referred to Costing & Pricing Division for fixation of price by the Federal Government under the Drug Pricing Policy. The certificate of registration will be issued after price fixation by Federal Government. 15. In case rejection of application by Registration Board, applicant has the right of appeal within 60 days before the Appellate Board. Output Criteria to exit the business process Output Criteria to exit the business process Validity for 5 years (unless earlier cancelled or suspended by the Registration Board) Legal Reference: Drug Regulatory Authority of Pakistan Act, 2012 and The Drug (Licensing, Registering & Advertising) Rules, 1976 Minimum: 03 months Maximum: 18 months		10. For imported drugs, GMP inspection of foreign manufacturer is carried out prior to grant of registration as per the policy on
12. If the Registration Board rejects the application, BE&R Division informs the applicant (manufacturer /importer) for rejection of application. 13. If MRP is already fixed by Federal Government, Biologica Evaluation & Research Division of DRAP issues Certificate of Registration of approved drug product to the applicant (manufacture / importer). 14. In case, the MRP is not fixed, matter is referred to Costing & Pricing Division for fixation of price by the Federal Government under the Drug Pricing Policy. The certificate of registration will be issued after price fixation by Federal Government. 15. In case rejection of application by Registration Board, applicant has the right of appeal within 60 days before the Appellate Board. Output Criteria to exit the business process • Certificate of Registration (Form 6) of drug product from DRAF office. • Validity for 5 years (unless earlier cancelled or suspended by the Registration Board) • Legal Reference: Drug Regulatory Authority of Pakistan Act, 2012 and The Drug (Licensing, Registering & Advertising) Rules, 1976 • Minimum: 03 months • Maximum: 18 months		<u> </u>
13. If MRP is already fixed by Federal Government, Biologica Evaluation & Research Division of DRAP issues Certificate o Registration of approved drug product to the applicant (manufacture / importer). 14. In case, the MRP is not fixed, matter is referred to Costing & Pricing Division for fixation of price by the Federal Government under the Drug Pricing Policy. The certificate of registration will be issued after price fixation by Federal Government. 15. In case rejection of application by Registration Board, applicant has the right of appeal within 60 days before the Appellate Board. Output Criteria to exit the business process • Validity for 5 years (unless earlier cancelled or suspended by the Registration Board) • Legal Reference: Drug Regulatory Authority of Pakistan Act, 2012 and The Drug (Licensing, Registering & Advertising) Rules, 1976 • Minimum: 03 months • Maximum: 18 months		12. If the Registration Board rejects the application, BE&R Division informs the applicant (manufacturer /importer) for rejection of
14. In case, the MRP is not fixed, matter is referred to Costing & Pricing Division for fixation of price by the Federal Government under the Drug Pricing Policy. The certificate of registration will be issued after price fixation by Federal Government. 15. In case rejection of application by Registration Board, applicant has the right of appeal within 60 days before the Appellate Board. Output Criteria to exit the business process • Certificate of Registration (Form 6) of drug product from DRAF office. • Validity for 5 years (unless earlier cancelled or suspended by the Registration Board) • Legal Reference: Drug Regulatory Authority of Pakistan Act, 2012 and The Drug (Licensing, Registering & Advertising) Rules, 1976 Time required to exit the business process • Maximum: 18 months		13. If MRP is already fixed by Federal Government, Biological Evaluation & Research Division of DRAP issues Certificate of Registration of approved drug product to the applicant (manufacturer
15. In case rejection of application by Registration Board, applicant has the right of appeal within 60 days before the Appellate Board. Output Criteria to exit the business process • Validity for 5 years (unless earlier cancelled or suspended by the Registration Board) • Legal Reference: Drug Regulatory Authority of Pakistan Act, 2012 and The Drug (Licensing, Registering & Advertising) Rules, 1976 Time required to exit the business process • Minimum: 03 months • Maximum: 18 months		14. In case, the MRP is not fixed, matter is referred to Costing & Pricing Division for fixation of price by the Federal Government under the Drug Pricing Policy. The certificate of registration will be issued after
to exit the business process • Validity for 5 years (unless earlier cancelled or suspended by the Registration Board) • Legal Reference: Drug Regulatory Authority of Pakistan Act, 2012 and The Drug (Licensing, Registering & Advertising) Rules, 1976 Time required to exit the business process • Maximum: 18 months		15. In case rejection of application by Registration Board, applicant has
Registration Board) Legal Reference: Drug Regulatory Authority of Pakistan Act, 2012 and The Drug (Licensing, Registering & Advertising) Rules, 1976 Time required to exit the business process Maximum: 18 months Maximum: 18 months	to exit the	office.
and The Drug (Licensing, Registering & Advertising) Rules, 1976 Time required to exit the business process and The Drug (Licensing, Registering & Advertising) Rules, 1976 Minimum: 03 months Maximum: 18 months	-	
exit the business process • Maximum: 18 months		
	exit the business	
The second secon	Fee	The updated fee structure of regulatory functions can be accessed on

https://www.dra.gov.pk/publications/regulatory-fees/.

Process Description for Grant of Drug Registration (Biological